¼¼°èÀÇ µ¿¹°¿ë ÇǺΰú ÀǾàǰ ½ÃÀå
Veterinary Dermatology Drugs
»óǰÄÚµå : 1773937
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 551 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,206,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,620,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

µ¿¹°¿ë ÇǺΰú ÀǾàǰ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 276¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 168¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â µ¿¹°¿ë ÇǺΰú ÀǾàǰ ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 8.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 276¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±â»ýÃæ °¨¿°ÁõÀº CAGR 8.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 162¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Ë·¹¸£±â ¼º°¨¿°Áõ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 9.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 46¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ µ¿¹°¿ë ÇǺΰú ÀǾàǰ ½ÃÀåÀº 2024³â¿¡ 46¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 60¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 13.2%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 4.4%¿Í 8.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ µ¿¹°¿ë ÇǺΰú ÀǾàǰ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

µ¿¹°¿ë ÇǺΰú ÀǾàǰÀÇ ¼ö¿ä°¡ ±ÞÁõÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

µ¿¹°¿ë ÇǺΰú ÀǾàǰ ½ÃÀåÀº ¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ ÇǺÎÁúȯ À¯º´·ü Áõ°¡·Î ÀÎÇØ Àü·Ê ¾ø´Â ¼ö¿ä Áõ°¡¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±â¼º ÇǺο°, ³óÇÇÁõ, ¿È, °õÆÎÀÌ °¨¿° µî ÇǺΠÁúȯÀÌ ¸¸¿¬Çϸ鼭 ¹Ý·Áµ¿¹° º¸È£ÀÚ¿Í Ãà»ê³ó°¡µéÀº È¿°úÀûÀÎ Ä¡·á¹ýÀ» ã°Ô µÇ¾ú½À´Ï´Ù. µ¿¹° °Ç°­¿¡ ´ëÇÑ º¸È£ÀÚÀÇ ÀÎ½Ä Áõ°¡, ¼öÀÇÇп¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó, ¹Ý·Áµ¿¹°ÀÇ Àΰ£È­ °æÇâ Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀÎÀÌ ÀÌ·¯ÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø´Ü µµ±¸¿Í ¿ø°ÝÀÇ·á Ç÷§ÆûÀÇ ¹ßÀüÀ¸·Î ¼öÀǻ簡 ÇǺΠÁúȯÀ» Á¶±â¿¡ Áø´ÜÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ó¹æÀü ±â¹Ý Ä¡·á°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°, ƯÈ÷ °³¿Í °í¾çÀ̴ ȯ°æ¿À¿°¹°Áú, À½½Ä¹° °ú¹ÎÁõ, ±â»ýÃæ °¨¿°À¸·Î ÀÎÇÑ ÇǺΠ¾Ë·¹¸£±â¿¡ ½Ã´Þ¸®°í ÀÖ¾î ÇǺΰú Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ãà»ê ³ó°¡µéÀº µ¿¹°ÀÇ º¹Áö¿Í »ý»ê¼ºÀ» ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, ÇǺΠ°¨¿°ÀÌ À¯·®, À°Áú, Àü¹ÝÀûÀÎ µ¿¹°ÀÇ °Ç°­¿¡ Å« ¿µÇâÀ» ¹ÌÄ£´Ù´Â °ÍÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä´Â ƯÈ÷ ¹Ý·Áµ¿¹° »çÀ° ¼ö°¡ »ç»ó ÃÖ°íÄ¡¸¦ ±â·ÏÇϰí ÀÖ´Â ¼±Áø±¹À» Áß½ÉÀ¸·Î Àü ¼¼°è ¹Ý·Áµ¿¹° ¼öÀÇ Áõ°¡·Î ÀÎÇØ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àμö°øÅëÀü¿°º´¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ µ¿¹°°ú Àΰ£ÀÇ °Ç°­ À¯Áö¿¡ ÀÖ¾î ÇǺΰú Ä¡·áÀÇ Á߿伺ÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© Ư¼ö µ¿¹°¿ë ÇǺΰú ÀǾàǰ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Á¦¾à»ç¿¡°Ô À¯¸®ÇÑ ºÐ¾ß°¡ µÇ°í ÀÖ½À´Ï´Ù.

µ¿¹°¿ë ÇǺΰú ÀǾàǰÀÇ ÃÖ÷´Ü Çõ½ÅÀ̶õ?

Á¦¾àȸ»çµéÀº Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ´Â Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ µ¿¹°¿ë ÇǺΰú ÀǾàǰÀ» µµÀÔÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­ °¡Àå ȹ±âÀûÀÎ ¹ßÀü Áß Çϳª´Â ¹Ý·Áµ¿¹°ÀÇ ¾Ë·¹¸£±â¼º ÇǺο°°ú ¾ÆÅäÇǼº ÇǺο°¿¡ ´ëÇÑ Ç¥Àû Ä¡·á¸¦ Á¦°øÇÏ´Â ´ÜŬ·ÐÇ×ü Ä¡·áÁ¦ÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ·¯ÇÑ »ý¹°ÇÐÀû Á¦Á¦¸¦ ÀÌ¿ëÇÑ Ä¡·á´Â ±âÁ¸ÀÇ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵峪 Ç×È÷½ºÅ¸¹ÎÁ¦¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í, ¿ÏÈ­ È¿°ú°¡ ¿À·¡ Áö¼ÓµÈ´Ù´Â Á¡¿¡¼­ Å« ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ß´©½º Ű³ª¾ÆÁ¦(JAK) ¾ïÁ¦Á¦¿Í °°Àº »õ·Î¿î ÀúºÐÀÚ ¾ïÁ¦Á¦¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ µ¿¹°ÀÇ ¿°Áõ¼º ÇǺÎÁúȯ Ä¡·á¹ý¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌµé ¾ïÁ¦Á¦´Â ¾Ë·¹¸£±â ¹ÝÀÀ¿¡ °ü¿©Çϴ ƯÁ¤ »çÀÌÅäÄ«ÀÎ °æ·Î¸¦ È¿°úÀûÀ¸·Î Â÷´ÜÇÏ¿© ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¤¹ÐÇÑ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, µ¿¹°¿ë ÇǺΰú ¿µ¿ª¿¡¼­´Â Ç×±Õ ÆéŸÀ̵å¿Í õ¿¬ »ý¸®È°¼º È­ÇÕ¹°À» ÇÔÀ¯ÇÑ ¾à¿ë ¼¤Çª, ½ºÇÁ·¹ÀÌ, ¿¬°í µî ±¹¼Ò¿ë ¾àÁ¦ Á¦Á¦°¡ µîÀåÇÏ¿© °¨¿°¼º ÁúȯÀÇ Ä¡·á¿Í µ¿½Ã¿¡ ÇǺΠÀ庮 º¸È£¸¦ °­È­ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇǺΰú Ä¡·áÀÇ »ýü ÀÌ¿ë·ü°ú È¿´ÉÀ» °³¼±Çϱâ À§ÇØ ³ª³ë±â¼úÀ» Ȱ¿ëÇÑ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÌ Á¶»çµÇ°í ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Æ®·»µå´Â ÇÁ·Î¹ÙÀÌ¿Àƽ½º¿Í ¹Ì»ý¹° ±â¹Ý Ä¡·á¹ýÀÇ ºÎ»óÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº µ¿¹°ÀÇ ÇǺΠ¹Ì»ý¹° ±ºÁýÀ» Á¶ÀýÇÏ¿© ÇǺÎÀÇ Ç×»ó¼ºÀ» ȸº¹½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. À¯ÀüÀÚ Ä¡·á¿Í Àç»ý ÀÇÇÐÀÇ ¹ßÀüÀº ¾ÆÁ÷ ½ÇÇè ´Ü°è¿¡ ÀÖÁö¸¸, ƯÁ¤ ǰÁ¾ÀÇ À¯Àü¼º ÇǺΠÁúȯÀ» Ä¡·áÇÏ´Â µ¥ À¯¸ÁÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÃÖ÷´Ü ±â¼ú Çõ½ÅÀº ¼öÀÇÇÐ ÇǺΰúÇÐÀÇ ÆÐ·¯´ÙÀÓ º¯È­¸¦ ¹Ý¿µÇϸç, ´ëÁõ¿ä¹ý¿¡¼­ Ä¡·á ¹× ¿¹¹æÀû Á¢±ÙÀ¸·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù.

±ÔÁ¦ Á¤Ã¥°ú ½ÃÀå ¿ªÇÐÀº ¾î¶»°Ô »ê¾÷À» Çü¼ºÇϰí Àִ°¡?

±ÔÁ¦ »óȲ°ú ½ÃÀå ¿ªÇÐÀº ÀÌ ºÐ¾ßÀÇ ¼ºÀå ±Ëµµ¸¦ Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¹Ì±¹°ú À¯·´¿¬ÇÕ(EU)¿¡¼­ µ¿¹°¿ë ÀǾàǰÀ» µÑ·¯½Ñ ¾ö°ÝÇÑ ±ÔÁ¦´Â ÀǾàǰ °³¹ß ¹× ½ÂÀÎ ÀýÂ÷¿¡ ´ëÇÑ ¾ö°ÝÇÑ ½É»ç¸¦ °­È­ÇÏ´Â °á°ú¸¦ ³º°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú À¯·´ÀǾàǰû(EMA)°ú °°Àº ±â°üÀº µ¿¹°¿ë ÀǾàǰÀÇ ¾ÈÀü¼º, À¯È¿¼º ¹× ǰÁúÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ ±âÁØÀ» Àû¿ëÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ Áؼö´Â ¸¹Àº Á¦Á¶¾÷üµé¿¡°Ô ¿©ÀüÈ÷ ¾î·Á¿î °úÁ¦ÀÌÁö¸¸, ÀÓ»ó½ÃÇèÀÌ ¿Ï·áµÇ°í Àß ¹®¼­È­µÈ Ä¡·á¹ý¸¸ÀÌ ½ÃÀå¿¡ Ãâ½ÃµÇ¾î ¼ÒºñÀÚÀÇ ½Å·Ú¸¦ ³ôÀÏ ¼ö ÀÖµµ·Ï º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¿ªÇÐÀº µ¿¹°¿ë ÀǾàǰ ±â¾÷ÀÇ ÅëÇÕ¿¡ ÀÇÇØ ´õ¿í ¿µÇâÀ» ¹Þ¾Æ ÁÖ¿ä ±â¾÷ °£ÀÇ °æÀïÀÌ ½ÉÈ­µÇ°í ÀÖ½À´Ï´Ù. ´ë±â¾÷µéÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ°í °æÀï ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇØ ÇǺΰúÇÐ ¼Ö·ç¼ÇÀ» Àü¹®À¸·Î ÇÏ´Â Áß¼Ò ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷À» Àû±ØÀûÀ¸·Î ÀμöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, E-Commerce¿Í µ¿¹°¿ë ÀǾàǰ Á÷°Å·¡ÀÇ ¿µÇâ·ÂÀÌ Ä¿Áö¸é¼­ µ¿¹°¿ë ÀǾàǰÀÇ À¯Åë ¹æ½Äµµ º¯È­Çϰí ÀÖ½À´Ï´Ù. ¿Â¶óÀÎ µ¿¹°¾à±¹ ¹× ¹Ý·Áµ¿¹° ÇコÄɾî Ç÷§ÆûÀº ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÌ ÇǺΰú Ä¡·áÁ¦¸¦ º¸´Ù ½±°Ô Á¢ÇÒ ¼ö ÀÖµµ·Ï Çϰí, ±âÁ¸ µ¿¹°º´¿ø¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß°í ÀÖ½À´Ï´Ù. ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿äÀÎÀº ¹Ý·Áµ¿¹° °Ç°­°ü¸®¿¡ ´ëÇÑ º¸Çè °è¾àÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÌ °æÁ¦Àû Á¦¾à ¾øÀÌ Á¾ÇÕÀûÀÎ Ä¡·á¸¦ ¼±ÅÃÇÒ ¼ö ÀÖµµ·Ï Àå·ÁÇϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ½ÅÈï±¹µµ °¡Ã³ºÐ ¼Òµæ Áõ°¡, µµ½ÃÈ­, ¹Ý·Áµ¿¹° °ü¸®¿¡ ´ëÇÑ »ç°í¹æ½ÄÀÇ º¯È­·Î ÀÎÇØ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª °¡°Ý ¾Ð¹Ú, Á¦³×¸¯ ÀǾàǰ°úÀÇ °æÀï, Ç×±ÕÁ¦ ³»¼º¿¡ ´ëÇÑ ¿ì·Á¿Í °°Àº µµÀü¿¡ Á÷¸éÇϰí ÀÖÀ¸¸ç, ÁÖ¿ä ±â¾÷µéÀÇ Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú Àü·«Àû ½ÃÀå Æ÷Áö¼Å´×ÀÌ ÇÊ¿äÇÑ »óȲÀÔ´Ï´Ù.

µ¿¹°¿ë ÇǺΰú ÀǾàǰ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

µ¿¹°¿ë ÇǺΰú ÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ¼ÒºñÀÚ ÇൿÀÇ º¯È­, µ¿¹° ÀÇ·á¿¡¼­ÀÇ ¿ëµµ È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ ÃËÁø¿äÀÎ Áß Çϳª´Â ¾Ë·¹¸£±â¼º ÇǺο° ¹× ¿°Áõ¼º ÇǺÎÁúȯÀ» Ç¥ÀûÈ­ÇÏ¿© Àå±âÀûÀ¸·Î ¿ÏÈ­½ÃŰ´Â ´ÜŬ·ÐÇ×ü ¹× JAK ¾ïÁ¦Á¦¿Í °°Àº »ý¹°ÇÐÀû Á¦Á¦ ¹× ¸é¿ª¿ä¹ý¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ±âÈĺ¯È­¿Í ȯ°æ¿À¿°À¸·Î ¾ÇÈ­µÈ ¹Ý·Áµ¿¹°ÀÇ ¾Ë·¹¸£±â ¹× ÇǺÎÁúȯ À¯º´·ü Áõ°¡·Î µ¿¹°º´¿ø ³»¿øÀÌ Áõ°¡Çϸ鼭 Àü¹® ¾àǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ý·Áµ¿¹°ÀÇ ÈÞ¸Ó´ÏÁ¦À̼Ç(Àΰ£È­) Æ®·»µå´Â ¹Ý·Áµ¿¹°ÀÇ °Ç°­°ü¸®¿¡ ´ëÇÑ º¸È£ÀÚµéÀÇ Á¢±Ù ¹æ½ÄÀ» º¯È­½ÃÄ×°í, ¸¹Àº º¸È£ÀÚµéÀÌ µ¿¹°ÀÇ °Ç°­À» À§ÇØ ¼öÀǻ簡 ó¹æÇÏ´Â °íǰÁú ÇǺΰú Ä¡·áÁ¦¿¡ ´õ ¸¹Àº ºñ¿ëÀ» ÁöºÒÇϱ⸦ ¿øÇϰí ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á¿Í ¿Â¶óÀÎ ¼öÀÇÇÐ »ó´ãÀÇ ±Þ¼ÓÇÑ È®´ë´Â ÇǺΰú Ä¡·á¿¡ ´ëÇÑ Á¢±ÙÀ» ¿ëÀÌÇÏ°Ô Çϰí, º¸È£ÀÚ°¡ ¿ø°ÝÁö¿¡¼­ Àü¹®°¡ÀÇ Á¶¾ð°ú ó¹æÀ» ¹ÞÀ» ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¿¹°¿ë ÇǺΰú ÀǾàǰÀº ÇǺκ´ÀÌ »ý»ê¼º¿¡ ¹ÌÄ¡´Â °æÁ¦Àû ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Ãà»ê ºÐ¾ß¿¡¼­µµ Å« È£ÀÀÀ» ¾ò°í ÀÖ½À´Ï´Ù. ³«³ó°¡µéÀº À¯·® °¨¼Ò, üÁß °¨¼Ò, À°Áú ÀúÇÏ·Î À̾îÁö´Â °¨¿°¼º ÁúȯÀ» ¿¹¹æÇϱâ À§ÇØ ÇǺΰú Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¼ºÀåÀ» ÃËÁøÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿äÀÎÀº Àü¹®ÀûÀÎ Ä¡·á·Î °í±Þ ÇǺΰú Ä¡·á¸¦ Á¦°øÇÏ´Â µ¿¹° Àü¹® Ŭ¸®´Ð°ú º´¿øÀÇ Á¸Àç°¨ÀÌ °­ÇÏ´Ù´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ Á¦¾à»çµéÀº °³¿Í °í¾çÀÌ¿¡¼­ ¸»°ú ¼Ò¿¡ À̸£±â±îÁö ´Ù¾çÇÑ µ¿¹°ÀÇ µ¶Æ¯ÇÑ ÇǺΠ»ý¸®¿¡ ´ëÀÀÇÏ´Â Á¾ ƯÀÌÀû ÇǺΰú Ä¡·áÁ¦ °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀΰøÁö´É(AI)À» žÀçÇÑ ¿µ»ó Áø´Ü ¹× Áø´Ü µµ±¸°¡ ÇǺΰú ÁúȯÀÇ Á¶±â ¹ß°ßÀ» °­È­Çϱâ À§ÇØ ¼öÀÇÇÐÀû Áø´Ü¿¡ ÀΰøÁö´É(AI)ÀÇ ÅëÇÕÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ½ÃÀåÀ» ´õ¿í ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ¹Ý·Áµ¿¹° »çÀ°·üÀÇ Áõ°¡¿Í ÇÔ²² ½ÅÈï±¹ ½ÃÀå È®´ë´Â ¼öÀÇÇǺΰú¸¦ ÇâÈÄ ¸î ³â µ¿¾È Áß¿äÇÑ ÅõÀÚ ºÐ¾ß·Î ¸¸µé °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÎ¹®

ÀûÀÀÁõ(±â»ýÃæ °¨¿°Áõ, ¾Ë·¹¸£±â ¼º°¨¿°Áõ, ±âŸ), À¯Çü(󹿾à, OTC), µ¿¹° À¯Çü(¹Ý·Áµ¿¹°, Ãà»êµ¿¹°), Åõ¿© °æ·Î(±¹¼Ò, °æ±¸, ÁÖ»ç), À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å, E-Commerce)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Veterinary Dermatology Drugs Market to Reach US$27.6 Billion by 2030

The global market for Veterinary Dermatology Drugs estimated at US$16.8 Billion in the year 2024, is expected to reach US$27.6 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Parasitic Infections, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$16.2 Billion by the end of the analysis period. Growth in the Allergic Infections segment is estimated at 9.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 13.2% CAGR

The Veterinary Dermatology Drugs market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.0 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global Veterinary Dermatology Drugs Market - Key Trends & Drivers Summarized

Why Is There a Surge in Demand for Veterinary Dermatology Drugs?

The veterinary dermatology drugs market is witnessing an unprecedented surge in demand, driven by the increasing prevalence of dermatological disorders in companion and livestock animals. Skin conditions such as allergic dermatitis, pyoderma, mange, and fungal infections are becoming more widespread, compelling pet owners and livestock farmers to seek effective treatment solutions. Factors such as heightened awareness among pet owners regarding animal health, improved access to veterinary care, and the growing trend of pet humanization have all contributed to this demand upswing. Moreover, veterinarians are increasingly diagnosing skin conditions earlier due to advancements in diagnostic tools and telemedicine platforms, which has led to a rise in prescription-based treatments. Companion animals, particularly dogs and cats, suffer from skin allergies due to environmental pollutants, food sensitivities, and parasitic infections, further escalating the demand for dermatological therapeutics. Additionally, livestock farmers are prioritizing animal welfare and productivity, recognizing that skin infections can significantly impact milk yield, meat quality, and overall animal health. This demand is further amplified by an increasing global population of pets, particularly in developed regions where pet ownership is at an all-time high. As awareness grows regarding zoonotic skin diseases, the importance of dermatological treatments in maintaining animal and human health has gained prominence. These elements combined are creating an expanding market for specialized veterinary dermatology drugs, making it a lucrative sector for pharmaceutical players.

What Are the Cutting-Edge Innovations in Veterinary Dermatology Drugs?

Pharmaceutical companies are investing heavily in research and development to introduce innovative and more effective veterinary dermatology drugs that offer enhanced therapeutic benefits. One of the most groundbreaking advancements in this field is the development of monoclonal antibody therapy, which provides targeted treatment for allergic dermatitis and atopic skin conditions in pets. Such biologic treatments have gained significant traction as they offer longer-lasting relief with fewer side effects compared to conventional corticosteroids and antihistamines. Additionally, the growing interest in novel small-molecule inhibitors, such as Janus kinase (JAK) inhibitors, is revolutionizing how inflammatory skin diseases in animals are managed. These inhibitors effectively block specific cytokine pathways involved in allergic responses, offering precision treatment with minimal adverse effects. The veterinary dermatology sector is also witnessing the rise of topical drug formulations, including medicated shampoos, sprays, and ointments infused with antimicrobial peptides and natural bioactive compounds, which enhance skin barrier protection while treating infections. Furthermore, nanotechnology-driven drug delivery systems are being explored to improve the bioavailability and efficacy of dermatological treatments. Another notable trend is the rise of probiotics and microbiome-based therapies, which aim to restore skin homeostasis by modulating microbial populations on animal skin. Advances in gene therapy and regenerative medicine, though still in experimental stages, hold promise for addressing hereditary dermatological disorders in certain dog breeds. These cutting-edge innovations reflect a paradigm shift in veterinary dermatology, shifting away from symptom management toward curative and preventative approaches.

How Are Regulatory Policies and Market Dynamics Shaping the Industry?

The regulatory landscape and market dynamics play a crucial role in shaping the growth trajectory of the veterinary dermatology drugs sector. Stringent regulations surrounding animal healthcare products, particularly in the United States and European Union, have led to increased scrutiny in drug development and approval processes. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose rigorous standards to ensure the safety, efficacy, and quality of veterinary pharmaceuticals. While regulatory compliance remains a challenge for many manufacturers, it also ensures that only clinically tested and well-documented treatments reach the market, enhancing consumer trust. The market dynamics are further influenced by the consolidation of veterinary pharmaceutical companies, leading to intensified competition among key industry players. Large corporations are actively acquiring smaller biotech firms specializing in dermatological solutions to expand their product portfolios and gain a competitive edge. Additionally, the rising influence of e-commerce and direct-to-consumer veterinary drug sales is changing how these products are distributed. Online veterinary pharmacies and pet healthcare platforms are making dermatology drugs more accessible to pet owners, reducing dependency on traditional veterinary clinics. Another important factor influencing market dynamics is the increasing adoption of insurance policies for pet healthcare, encouraging owners to opt for comprehensive treatments without financial constraints. Emerging economies in Asia-Pacific and Latin America are also experiencing significant market expansion due to increasing disposable incomes, urbanization, and evolving attitudes toward pet care. However, the market faces challenges such as pricing pressures, competition from generic alternatives, and concerns over antimicrobial resistance, necessitating continuous innovation and strategic market positioning by key players.

What Are the Key Growth Drivers for the Veterinary Dermatology Drugs Market?

The growth in the veterinary dermatology drugs market is driven by several factors, including technological advancements, changing consumer behavior, and expanding applications in veterinary medicine. One of the most significant drivers is the increasing preference for biologics and immunotherapies, such as monoclonal antibodies and JAK inhibitors, which provide targeted and long-lasting relief from allergic dermatitis and inflammatory skin disorders. The rising prevalence of pet allergies and dermatological conditions, exacerbated by climate change and environmental pollution, has led to increased veterinary visits and a higher demand for specialized medications. Additionally, the growing trend of pet humanization has transformed how pet owners approach healthcare, with many willing to spend more on high-quality, vet-prescribed dermatology drugs to ensure their animals’ well-being. The rapid expansion of telemedicine and online veterinary consultations has also facilitated greater accessibility to dermatological treatments, allowing pet owners to seek expert advice and prescriptions remotely. Furthermore, veterinary dermatology drugs are gaining traction in the livestock sector, where there is heightened awareness regarding the economic impact of skin diseases on productivity. Farmers are increasingly investing in dermatological treatments to prevent infections that could lead to reduced milk production, weight loss, and lower meat quality. Another significant factor driving growth is the strong presence of veterinary specialty clinics and hospitals, which offer advanced dermatology care with specialized treatments. Moreover, pharmaceutical companies are focusing on developing species-specific dermatological drugs, catering to the unique skin physiology of different animals, from dogs and cats to horses and cattle. The increasing integration of artificial intelligence (AI) in veterinary diagnostics is further propelling the market forward, as AI-powered imaging and diagnostic tools enhance the early detection of dermatological disorders. Lastly, market expansion in emerging economies, coupled with rising pet adoption rates, is expected to further accelerate growth, making veterinary dermatology a key area of investment in the coming years.

SCOPE OF STUDY:

The report analyzes the Veterinary Dermatology Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Parasitic Infections, Allergic Infections, Others); Type (Prescription, OTC); Animal Type (Companion Animals, Livestock Animals); Administration Route (Topical, Oral, Injectable); Distribution Channel (Hospital Pharmacies, Retail, E-Commerce)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â